Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus

Wan Long Chuang, Rong Nan Chien, Cheng Yuan Peng, Ting Tsung Chang, Gin Ho Lo, I. Shyan Sheen, Horng Yuan Wang, Jyh Jou Chen, Jenny C. Yang, Steven J. Knox, Bing Gao, Kimberly L. Garrison, Hongmei Mo, Phillip S. Pang, Yu Chun Hsu, Tsung Hui Hu, Chi Jen Chu, Jia Horng Kao

研究成果: Article

22 引文 斯高帕斯(Scopus)

摘要

Background and Aim:: Pegylated-interferon-alpha plus ribavirin is the current standard-of-care regimen for treating chronic hepatitis C virus (HCV) infection in Taiwan; however, interferon-based regimens can be poorly tolerated. The interferon-free, two-drug, fixed-dose combination tablet ledipasvir/sofosbuvir is approved in Europe, the USA, and Japan for treating chronic genotype 1 HCV infection. Little is known about its efficacy/safety in Taiwanese patients. Methods:: In this multicenter, open-label, phase 3b (NCT02021656) study, 85 Taiwanese patients (n = 42, treatment-naïve; n = 43, treatment-experienced) with chronic genotype 1 HCV infection (±compensated cirrhosis) received 12 weeks of ledipasvir/sofosbuvir fixed-dose combination tablet. The primary efficacy end point was the proportion of patients with sustained virologic response 12 weeks after treatment discontinuation (SVR12). Safety and pharmacokinetic data were collected. Results:: The overall SVR12 rate was 98% (83/85), with 100% (42/42) and 95% (41/43) of treatment-naïve and treatment-experienced patients, respectively, achieving SVR12. There were no on-treatment virologic failures. One patient relapsed after treatment discontinuation; one patient withdrew consent on day 2. The most common treatment-emergent adverse event (AE) was headache (14%, 12/85). There was one grade 3 AE (small cell lung cancer unrelated to ledipasvir/sofosbuvir), no grade 4 AEs, and four grade 3–4 laboratory abnormalities. Only the patient with small cell lung cancer prematurely discontinued treatment. Two patients reported three serious AEs; none was considered related to ledipasvir/sofosbuvir. Conclusions:: Data from this phase 3b study suggest that 12 weeks of once-daily treatment with the interferon-free, ribavirin-free regimen ledipasvir/sofosbuvir is effective and well-tolerated in Taiwanese patients with chronic genotype 1 HCV infection, irrespective of treatment history.

原文English
頁(從 - 到)1323-1329
頁數7
期刊Journal of Gastroenterology and Hepatology (Australia)
31
發行號7
DOIs
出版狀態Published - 2016 七月 1

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

指紋 深入研究「Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus」主題。共同形成了獨特的指紋。

  • 引用此

    Chuang, W. L., Chien, R. N., Peng, C. Y., Chang, T. T., Lo, G. H., Sheen, I. S., Wang, H. Y., Chen, J. J., Yang, J. C., Knox, S. J., Gao, B., Garrison, K. L., Mo, H., Pang, P. S., Hsu, Y. C., Hu, T. H., Chu, C. J., & Kao, J. H. (2016). Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. Journal of Gastroenterology and Hepatology (Australia), 31(7), 1323-1329. https://doi.org/10.1111/jgh.13305